Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
The Californer/10220990

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.

The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

More on The Californer

• Historic 1947 Trumpy Yacht Mauretania Featured in Wooden Boat Magazine
• California Music Hall of Fame 2025 Induction Ceremony at Warner Bros. Studios November 15th
• Angel Light Academy Honors 8 Community Members Who Demonstrate Excellence in Leadership and Service 18th Annual Above & Beyond Awards November 8
• Culture, Classical Guitar and Comedy... HealthyLife.net Radio adds new programs
• THINKWARE to Showcase Three Next-Generation Dash Cams at SEMA Show

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

More on The Californer

• ICYMI: Coreshell Technologies wins $1 million grand prize at Startup World Cup Grand Finale, highlighting California's entrepreneurial leadership
• Small-Firm Leaders Must Prioritize High-Impact Tasks to Prevent Burnout: New Article in AT
• Stockdale Capital Partners Acquires 266-Unit Class-A Scottsdale, AZ Multifamily Community
• Revenue Optics Ignites AI Revolution in Industrial Distribution
• Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

Contacts

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

---

Show All News | Report Violation